Craig Parker
Tracked across 1 events · 7 articles · First seen Sep 08, 2026 · Last active Sep 08, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Surrozen, Inc. announced the submission of an Investigational New Drug (IND) application to the U.S. United States — Food and Drug Administration for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment…
Impact: Craig Parker, CEO of Surrozen, is the public spokesperson for the announcement. His leadership is central to the company's strategic direction, though the event does not directly affect him personally.
Sep 08, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Craig Parker live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard